Literature DB >> 1714971

Tumor induction in a rat model for ureterosigmoidostomy without evidence of nitrosamine formation.

T Kälble1, A R Tricker, M Berger, F Amelung, R Waldherr, L Hothorn, K Möhring, G Staehler.   

Abstract

Twenty rats were randomized into a vesicosigmoidostomy and an unoperated control group. In both groups the 24 hour excretion of secondary amines, nitrate, nitrite and nitrosamines was measured before and after gavage of proline and nitrate, piperazine and nitrate, N-nitrosoproline, mono-N-nitrosopiperazine. The urinary nitrosamine concentrations were not significantly different between both groups neither before nor after application of the several substances. Thirty rats were randomized into two vesicosigmoidostomy groups with and without antibiotic coverage and an unoperated control group. After ligation of distal rectum and mesosigmoid the rectosigmoids were removed. No significant concentrations of volatile nitrosamines could be measured in the rectosigmoid contents of the three groups. One hundred and twenty rats randomized into three groups following vesicosigmoidostomy received the potential nitrosamine antidotes sodium-2-mercaptoethane sulfonate or sodiumpentosan-polysulfate or acted as controls. 12/118 (10.2%) developed adenomas and 25/118 (21.2%) adenocarcinomas at the vesico-colonic anastomosis with no significant differences between the three groups concerning tumor incidence or mortality. The results show that colon carcinomas occur in a rat model for ureterosigmoidostomy without evidence for thus induced nitrosamine formation. This and the missing effect of nitrosamine antidotes suggest that other factors than nitrosation must be responsible for colon carcinogenesis following urinary diversion via intestine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714971     DOI: 10.1016/s0022-5347(17)37949-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  [Secondary malignancies in urinary diversions].

Authors:  T Kälble; I Hofmann; J W Thüroff; R Stein; R Hautmann; H Riedmiller; D Vergho; L Hertle; C Wülfing; M Truß; S Roth; F C von Rundstedt; P Albers; J Gschwend; K Herkommer; U Humke; M Spahn; P Bader; J Steffens; R Harzmann; C G Stief; A Karl; S C Müller; M Waldner; J Noldus; K Kleinschmidt; P Alken; B Kopper; M Fisch; A Lampel; A Stenzel; J Fichtner; B Flath; H Rübben; K P Juenemann; S Hautmann; A Knipper; D Leusmann; W Strohmaier; W F Thon; S Miller; K Weingärtner; A Schilling; H Piechota; J E Becht; H Schwaibold; P Bub; S Conrad; U Wenderoth; W Merkle; W Rösch; T Otto; B Ulshöfer; M Westenfelder
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

2.  Tumor induction and prophylaxis following different forms of intestinal urinary diversion in a rat model.

Authors:  T Kälble; K Busse; F Amelung; R Waldherr; M R Berger; L Edler; H Riedmiller
Journal:  Urol Res       Date:  1995

Review 3.  Tumour formation within intestinal segments transposed to the urinary tract.

Authors:  Robert Pickard
Journal:  World J Urol       Date:  2004-08-13       Impact factor: 4.226

4.  De Novo Secondary Adenocarcinoma in the Colon Used as Urinary Diversion Not in Contact with the Fecal Stream: Systematic Review and Meta-analysis.

Authors:  Antonio V Sterpetti; Umberto Costi; Raffaele Grande; Giuseppe D'Ermo; Paolo Sapienza
Journal:  Ann Surg Oncol       Date:  2020-03-05       Impact factor: 5.344

5.  Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case.

Authors:  Henry B Armah; Alyssa M Krasinskas; Anil V Parwani
Journal:  Diagn Pathol       Date:  2007-08-13       Impact factor: 2.644

6.  Continent urinary diversion.

Authors:  Andrew Moon; Nikhil Vasdev; Andrew C Thorpe
Journal:  Indian J Urol       Date:  2013-10

7.  An unusual diverticulum adjacent to two large colonic polyps; a case report.

Authors:  John Schembri; Jonathan Bury; Lesley Hunt; Stuart Riley
Journal:  BMC Gastroenterol       Date:  2018-06-14       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.